The case for & against
Bull & Bear analysis
Bullish
NRC Health (NASDAQ: NRC) operates as a dominant player within the healthcare insights sector, providing healthcare organizations with essential tools and analytics aimed at enhancing patient experiences and operational efficiencies. The company's extensive suite of services includes experience measurement and engagement solutions, positioning NRC Health as a key strategic partner to numerous U.S. health systems. As healthcare becomes increasingly consumer-driven and data-oriented, NRC Health’s solutions are pivotal in supporting organizations navigating these demands.
Bull says
- ↑Total Recurring Contract Value reached $152M (↑13% YoY)
- ↑Revenue grew 4% YoY to $35M in Q1 2026
- ↑Adjusted EBITDA margin improved to 27%; cost management effective
- ↑Free cash flow nearly doubled to $5.3M, boosting cash generation
- ↑$60M share buyback plus $0.16/share dividend underlines shareholder focus
- ↑AI-driven sentiment analysis and engagement tools expanding service depth
Bear says
- ↓Major client concentration exposes revenue to deal losses
- ↓Seasonal survey-driven revenue swings create growth volatility
- ↓Operational challenges in internal restructuring and AI integration
- ↓Competitive pressure from Qualtrics-Prescani tie-up and industry consolidations
- ↓Investor sentiment weak: high short interest and negative growth outlook
- ↓Low institutional ownership highlights limited confidence from major holders
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 04-30-2026neutral
Transcript signals
Bull points
- Our total recurring contract value, or TRCV, increased 13% year-over-year to an all-time high of $152 million, which is $8 million higher than where we finished Q4 2025.
- Q1 new sales bookings were up over 200% year over year, driven primarily by a landmark deal I'll describe in a moment.
- Revenue returned a positive year-over-year growth for the first time since 2023, increasing 4% to $35 million, and we improved our adjusted EBITDA margin sequentially by 2 points to 27%.
Bear points
- It has maybe slowed a few of our buying processes, but not in any way significantly.
- First quarter revenue did show a slight sequential decline from Q4 due to seasonality related to conference and point-in-time survey revenue.
- EBITDA margin was lower than Q1 2025 due to higher operating expenses tied to our executive team expansion, which is now complete, higher corporate expenses due to isolated brand and tax studies, and typical annual merit increases.
Read full transcript analysis ›